ASPHF
Price
$8.48
Change
+$0.74 (+9.56%)
Updated
Nov 26 closing price
Capitalization
2.86B
Intraday BUY SELL Signals
NURPF
Price
$11.01
Change
-$1.24 (-10.12%)
Updated
Dec 1 closing price
Capitalization
1.59B
Intraday BUY SELL Signals
Interact to see
Advertisement

ASPHF vs NURPF

Header iconASPHF vs NURPF Comparison
Open Charts ASPHF vs NURPFBanner chart's image
ASCENTAGE PHARMA GROUP
Price$8.48
Change+$0.74 (+9.56%)
Volume$100
Capitalization2.86B
Neuren Pharmaceuticals
Price$11.01
Change-$1.24 (-10.12%)
Volume$2.9K
Capitalization1.59B
ASPHF vs NURPF Comparison Chart in %
ASPHF
Daily Signal:
Gain/Loss:
NURPF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ASPHF vs. NURPF commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASPHF is a Hold and NURPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (ASPHF: $8.48 vs. NURPF: $11.01)
Brand notoriety: ASPHF and NURPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASPHF: 3% vs. NURPF: 190%
Market capitalization -- ASPHF: $3.04B vs. NURPF: $1.59B
ASPHF [@Biotechnology] is valued at $3.04B. NURPF’s [@Biotechnology] market capitalization is $1.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASPHF’s FA Score shows that 0 FA rating(s) are green whileNURPF’s FA Score has 2 green FA rating(s).

  • ASPHF’s FA Score: 0 green, 5 red.
  • NURPF’s FA Score: 2 green, 3 red.
According to our system of comparison, NURPF is a better buy in the long-term than ASPHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASPHF’s TA Score shows that 0 TA indicator(s) are bullish while NURPF’s TA Score has 3 bullish TA indicator(s).

  • ASPHF’s TA Score: 0 bullish, 2 bearish.
  • NURPF’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, NURPF is a better buy in the short-term than ASPHF.

Price Growth

ASPHF (@Biotechnology) experienced а +9.63% price change this week, while NURPF (@Biotechnology) price change was -10.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASPHF($2.86B) has a higher market cap than NURPF($1.59B). ASPHF YTD gains are higher at: 215.242 vs. NURPF (45.443). NURPF has higher annual earnings (EBITDA): 182M vs. ASPHF (-1.09B). ASPHF has higher revenues than NURPF: ASPHF (391M) vs NURPF (217M).
ASPHFNURPFASPHF / NURPF
Capitalization2.86B1.59B179%
EBITDA-1.09B182M-596%
Gain YTD215.24245.443474%
P/E RatioN/A14.73-
Revenue391M217M180%
Total Cash1.66BN/A-
Total Debt1.72BN/A-
FUNDAMENTALS RATINGS
NURPF: Fundamental Ratings
NURPF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
42
SMR RATING
1..100
18
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
18
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ASPHFNURPF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 6 days ago
64%
Momentum
ODDS (%)
Bearish Trend 6 days ago
38%
Bullish Trend 6 days ago
65%
MACD
ODDS (%)
Bearish Trend 6 days ago
43%
Bullish Trend 6 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
36%
Bullish Trend 6 days ago
62%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
28%
Bearish Trend 6 days ago
58%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 6 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ASPHF
Daily Signal:
Gain/Loss:
NURPF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRBRX195.00N/A
N/A
Franklin Biotechnology Discovery R6
BIREX15.10N/A
N/A
BlackRock Real Estate Securities Instl
MXINX15.77N/A
N/A
Empower International Index Inv
JRARX95.89N/A
N/A
Janus Henderson Research R
LIFLX16.07N/A
N/A
Lord Abbett Focused Large Cap Value I

ASPHF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASPHF has been loosely correlated with CGEN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPHF jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASPHF
1D Price
Change %
ASPHF100%
N/A
CGEN - ASPHF
41%
Loosely correlated
-0.33%
CLLS - ASPHF
34%
Loosely correlated
+1.18%
CMVLF - ASPHF
34%
Loosely correlated
N/A
NURPF - ASPHF
30%
Poorly correlated
N/A
ALDX - ASPHF
27%
Poorly correlated
-7.25%
More

NURPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NURPF has been loosely correlated with CGEN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NURPF jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NURPF
1D Price
Change %
NURPF100%
N/A
CGEN - NURPF
46%
Loosely correlated
-0.33%
ASPHF - NURPF
30%
Poorly correlated
N/A
SPHRF - NURPF
22%
Poorly correlated
N/A
KRRO - NURPF
21%
Poorly correlated
-0.93%
GDTC - NURPF
21%
Poorly correlated
-3.87%
More